Valuation: StimCell Energetics Inc.

Market Cap 6.64M 5.83M 5.36M 5M 9.43M 631M 9.62M 64.53M 25M 310M 24.93M 24.39M 1.08B P/E 2026 *
-7.85x
P/E 2027 * -15.7x
Enterprise Value 7.44M 6.53M 6.01M 5.6M 10.56M 707M 10.78M 72.3M 28.01M 347M 27.93M 27.32M 1.21B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
28.33%
Yield 2026 *
-
Yield 2027 * -
1 day-10.29%
1 week-10.29%
1 month-10.00%
3 months-6.32%
6 months-21.50%
Current year-21.50%
1 week 0.29
Extreme 0.29
0.35
1 month 0.29
Extreme 0.29
0.35
Current year 0.28
Extreme 0.281
0.48
1 year 0.25
Extreme 0.25
0.48
3 years 0
Extreme 0.0015
13.97
5 years 0
Extreme 0
13.97
10 years 0
Extreme 0
25.35
Manager TitleAgeSince
Chief Executive Officer 56 11/12/2023
Director of Finance/CFO 48 23/11/2014
Director TitleAgeSince
Director/Board Member 56 11/12/2023
Director/Board Member 62 07/06/2020
Chairman 78 25/02/2024
Date Insider Type Main position Quantity % Market Cap.
12-17Sell

Director

16,667 0.0807%
16/03/25Tax

Director

60,841,472 307.0278%
24/02/25Buy 15,000 0.0757%
Change 5-day change 1-year change 3-year change Capi.($)
-10.29%-10.29%-13.19%+74.44% 6.64M
+3.08%+6.47%-0.25%+5.47% 47.18B
+0.12%+10.45%+408.29%+600.97% 39.82B
+5.17%+9.47%+24.96%-9.60% 32.25B
+2.02%+4.91%+18.59%+63.06% 31.68B
+0.69%+1.04%+14.23%+30.86% 24.59B
+0.40%+12.51% - - 16.57B
+2.64%+6.00%+69.30%+126.33% 15.12B
-0.15%+2.15%+12.64%+17.71% 13.69B
+0.77%+10.67%+17.58%-30.04% 13.31B
Average +0.45%+5.26%+61.35%+97.69% 23.42B
Weighted average by Cap. +1.93%+7.03%+89.34%+130.43%

Financials

2026 *2027 *
Net sales - -
Net income -792M -696M -640M -597M -1.13B -75.34B -1.15B -7.7B -2.98B -36.98B -2.98B -2.91B -129B -510M -448M -412M -384M -724M -48.49B -739M -4.96B -1.92B -23.8B -1.91B -1.87B -82.83B
Net Debt 800K 702K 647K 602K 1.14M 76.06M 1.16M 7.78M 3.01M 37.33M 3M 2.94M 130M 800K 702K 647K 602K 1.14M 76.06M 1.16M 7.78M 3.01M 37.33M 3M 2.94M 130M
Logo StimCell Energetics Inc.
StimCell Energetics Inc. is a biotech company, which is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System. eBalance is a non-invasive, fully automated microcurrent electrotherapy system administering pre-programmed algorithms through the epidermis at the touch of a button to help you gain optimal wellness and reduce pain. Its eBalance represents a monumental stride in the realm of medical technology designed to rejuvenate and re-energize the human body at a cellular level. The operation of eBalance is an intricate process of precision engineering and human biology.
Employees
1
Date Price Change Volume

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STME Stock